A Study of LY2940680 in Small Cell Lung Cancer

NCT01722292 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Change in clinical strategy.

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: LY2940680
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Placebo

Sponsor

Eli Lilly and Company